XML 26 R8.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLANS	6 Months Ended
Jun. 30, 2015
Liquidity And Managements Plans
LIQUIDITY AND MANAGEMENT'S PLANS	(2) LIQUIDITY AND MANAGEMENT’S PLANS The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of June 30, 2015, the Company had cash of approximately $337,000, working capital deficit of approximately $2,165,000 and an accumulated deficit of approximately $147,000,000. The Company continues to incur recurring losses from operations. The Company will need to secure additional capital to fund its product development, research, manufacturing and clinical programs in accordance with its current planned operations. The Company has funded its operations in the past primarily through debt and equity issuances. Management will continue to pursue financing to fund its operations. No assurances can be given that additional capital will be available on terms acceptable to the Company. The accompanying financial statements do not include any adjustments that might result from the outcome of the uncertainty. Subsequent to June 30, 2015, the Company received the final installment of cash proceeds of $500,000 from a $4,000,000 equity financing it had arranged in December 2014.

LIQUIDITY AND MANAGEMENT'S PLANS

6 Months Ended

Jun. 30, 2015

(2) LIQUIDITY AND MANAGEMENT’S PLANS

The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of June 30, 2015, the Company had cash of approximately $337,000, working capital deficit of approximately $2,165,000 and an accumulated deficit of approximately $147,000,000. The Company continues to incur recurring losses from operations. The Company will need to secure additional capital to fund its product development, research, manufacturing and clinical programs in accordance with its current planned operations. The Company has funded its operations in the past primarily through debt and equity issuances. Management will continue to pursue financing to fund its operations. No assurances can be given that additional capital will be available on terms acceptable to the Company. The accompanying financial statements do not include any adjustments that might result from the outcome of the uncertainty.

Subsequent to June 30, 2015, the Company received the final installment of cash proceeds of $500,000 from a $4,000,000 equity financing it had arranged in December 2014.